학술논문
Retrospective observational analysis of bevacizumab (BV) plus paclitaxel (TXL) as first line treatment in metastatic HER2 negative breast cancer (BC): are BV long responders a different subgroup?
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15698041